

Maria Franca Pirillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5356704/publications.pdf>

Version: 2024-02-01

92
papers

1,865
citations

331259

21
h-index

301761

39
g-index

96
all docs

96
docs citations

96
times ranked

2854
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	5.8	297
2	Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. <i>Aids</i> , 2003, 17, 1597-1604.	1.0	110
3	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2109-2117.	1.4	101
4	Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. <i>Aids</i> , 2000, 14, 251-261.	1.0	86
5	Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. <i>Journal of Medical Virology</i> , 2007, 79, 1797-1801.	2.5	65
6	Triple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral Load. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 286-291.	0.9	61
7	Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 309-315.	1.1	57
8	Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. <i>PLoS ONE</i> , 2013, 8, e68950.	1.1	56
9	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with ≥ 50copies/ml HIV-1 RNA. <i>Journal of Clinical Virology</i> , 2009, 46, 367-370.	1.6	54
10	Residual viraemia in subjects with chronic HIV infection and viral load <math>< 50</math> copies/ml: the impact of highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 1843-1847.	1.0	47
11	Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. <i>Journal of Clinical Virology</i> , 2010, 47, 4-7.	1.6	45
12	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. <i>AIDS Patient Care and STDs</i> , 2009, 23, 513-520.	1.1	39
13	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. <i>Antiviral Therapy</i> , 2012, 17, 1511-1519.	0.6	37
14	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1472-1481.	1.8	36
15	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 39-47.	0.9	36
16	Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1466-1476.	1.1	34
17	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1027-1030.	1.3	32
18	Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. <i>Antiviral Research</i> , 1996, 29, 91-93.	1.9	28

#	ARTICLE	IF	CITATIONS
19	Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration. <i>Annals of Pharmacotherapy</i> , 2010, 44, 838-843.	0.9	26
20	Quality of life outcomes of combination zidovudine+didanosine+nevirapine and zidovudine+didanosine for antiretroviral-naïve advanced HIV-infected patients. <i>Aids</i> , 2000, 14, 2567-2574.	1.0	24
21	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. <i>HIV Medicine</i> , 2002, 3, 75-84.	1.0	22
22	Evaluation of a Second-Generation Nucleic Acid Sequence-Based Amplification Assay for Quantification of HIV Type 1 RNA and the Use of Ultrasensitive Protocol Adaptations. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1507-1517.	0.5	21
23	Treatment Change in Pregnancy Is a Significant Risk Factor for Detectable HIV-1 RNA in Plasma at End of Pregnancy. <i>HIV Clinical Trials</i> , 2010, 11, 303-311.	2.0	21
24	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. <i>Antiviral Research</i> , 1997, 36, 81-90.	1.9	19
25	Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. <i>Annals of Oncology</i> , 2002, 13, 1157-1159.	0.6	19
26	HCV+HIV coinfecting pregnant women: data from a multicentre study in Italy. <i>Infection</i> , 2016, 44, 235-242.	2.3	19
27	Correlation between Changes in Plasma HIV RNA Levels and in Plasma Infectivity in Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 555-561.	0.5	18
28	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mm ³). <i>HIV Medicine</i> , 2004, 5, 1-10.	1.0	17
29	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. <i>Viruses</i> , 2021, 13, 355.	1.5	17
30	Quantification of HIV-RNA from dried blood spots using the Siemens VERSANT(R) HIV-1 RNA (kPCR) assay. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2823-2826.	1.3	15
31	Voluntary pregnancy termination among women with HIV in the HAART era (2002-2008): a case series from a national study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 50-53.	0.6	14
32	Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1218-1223.	1.1	14
33	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment ¹ . <i>Antiviral Research</i> , 2000, 47, 189-198.	1.9	13
34	Pregnancy Outcomes in Women with Advanced HIV Infection in Italy. <i>AIDS Patient Care and STDs</i> , 2011, 25, 639-645.	1.1	13
35	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. <i>Journal of Medical Virology</i> , 2012, 84, 1553-1557.	2.5	13
36	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. <i>Journal of Viral Hepatitis</i> , 2015, 22, 289-296.	1.0	13
38	Lipid Profile During Pregnancy in HIV-Infected Women. <i>HIV Clinical Trials</i> , 2006, 7, 184-193.	2.0	12
39	Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 250-258.	0.9	12
40	The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. <i>BMC Infectious Diseases</i> , 2014, 14, 180.	1.3	12
41	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. <i>HIV Clinical Trials</i> , 2008, 9, 287-297.	2.0	11
42	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 477-481.	1.0	11
43	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. <i>HIV Clinical Trials</i> , 2014, 15, 104-115.	2.0	11
44	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. <i>Aids</i> , 2007, 21, 2360-2362.	1.0	10
45	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	0.5	10
46	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1479-1485.	1.3	10
47	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	1.3	10
48	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 418-428.	1.8	10
49	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	0.5	9
50	Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 101-110.	1.0	9
51	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 707-711.	0.5	9
52	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 71-77.	0.5	9
53	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 737-742.	0.5	9
54	Trough Concentrations of Lopinavir, Nelfinavir, and Nevirapine With Standard Dosing in Human Immunodeficiency Virus-Infected Pregnant Women Receiving 3-Drug Combination Regimens. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 604-610.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi. <i>Infectious Diseases</i> , 2017, 49, 708-711.	1.4	8
56	Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. <i>HIV Medicine</i> , 2017, 18, 440-443.	1.0	8
57	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 541-545.	0.5	7
58	Use of Specific Antiretroviral Regimens Among HIV-Infected Women in Italy at Time of Conception: 2001-2011. <i>AIDS Patient Care and STDs</i> , 2012, 26, 439-443.	1.1	7
59	HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. <i>Journal of Medical Virology</i> , 2016, 88, 2115-2124.	2.5	7
60	CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. <i>Medical Microbiology and Immunology</i> , 2017, 206, 23-29.	2.6	7
61	Seasonal Betacoronavirus Antibodies TM Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. <i>Journal of Clinical Immunology</i> , 2022, 42, 448-458.	2.0	7
62	Long-Term Evaluation of Cellular Immunity during Antiretroviral Therapy and Immunization with Human Immunodeficiency Virus Type 1 (HIV-1) Env Glycoprotein in HIV-1-Infected Persons. <i>Journal of Infectious Diseases</i> , 1997, 176, 904-912.	1.9	6
63	Declining HCV seroprevalence in pregnant women with HIV. <i>Epidemiology and Infection</i> , 2010, 138, 1317-1321.	1.0	6
64	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. <i>Frontiers in Immunology</i> , 2021, 12, 750386.	2.2	6
65	Tumor Necrosis Factor- α , Interleukin-10, and β -Defensins in Plasma and Breast Milk of HIV-Infected Highly Active Antiretroviral Therapy-Treated and Untreated Pregnant Women in Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 647-649.	0.9	5
66	Rubella Susceptibility Profile in Pregnant Women with HIV. <i>Clinical Infectious Diseases</i> , 2011, 52, 960-962.	2.9	5
67	Antibody response to hepatitis B vaccine in HIV-exposed infants in Malawi and correlation with HBV infection acquisition. <i>Journal of Medical Virology</i> , 2018, 90, 1172-1176.	2.5	5
68	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 68-71.	0.9	4
69	HIV-1 coreceptor switch during 2 years of structured treatment interruptions. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1565-1570.	1.3	4
70	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. <i>HIV Clinical Trials</i> , 2013, 14, 110-119.	2.0	4
71	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 263-275.	1.8	4
72	Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens. <i>Antiviral Therapy</i> , 2020, 25, 315-325.	0.6	4

#	ARTICLE	IF	CITATIONS
73	A simplified HAART Regimen with Raltegravir and Lamivudine and pharmacokinetic interactions with a combined immunosuppressive therapy with tacrolimus and everolimus in an HIV/HCV/HBV/HDV patient after Liver Transplantation. <i>West Indian Medical Journal</i> , 2014, 63, 779-84.	0.4	4
74	Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 785-790.	1.0	3
75	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. <i>Prenatal Diagnosis</i> , 2015, 35, 1374-1378.	1.1	3
76	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 491-492.	2.8	3
77	High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women. <i>Journal of Clinical Virology</i> , 2017, 96, 17-19.	1.6	3
78	Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 99-104.	0.9	3
79	Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1025-1030.	1.3	3
80	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. <i>AIDS Patient Care and STDs</i> , 2009, 23, 147-152.	1.1	2
81	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 749-752.	1.3	2
82	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	2.8	2
83	Pregnant with HIV before age 25: data from a large national study in Italy, 2001-2016. <i>Epidemiology and Infection</i> , 2017, 145, 2360-2365.	1.0	2
84	HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa. <i>Antiviral Therapy</i> , 2018, 23, 191-195.	0.6	2
85	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2
86	Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. <i>Journal of Medical Microbiology</i> , 2009, 58, 121-124.	0.7	1
87	Glucose Plasma Levels and Pregnancy Outcomes in Women with HIV. <i>HIV Clinical Trials</i> , 2011, 12, 299-312.	2.0	1
88	Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 673-678.	0.5	1
89	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1190-1193.	2.9	0
90	CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy. <i>Infection</i> , 2021, 49, 955-964.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Lack of new HBV infections over 2 years of follow-up in HIV-positive women receiving ART up to 6 or 24 months after delivery. <i>Journal of Infection in Developing Countries</i> , 2018, 12, 394-396.	0.5	0
92	Markers of microbial translocation during pregnancy: differences among HIV+ women of African and European provenance. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 184-190.	0.5	0